The intracellular pathogen Chlamydia trachomatis possesses a type III secretion (TTS) system believed to deliver a series of effector proteins into the inclusion membrane (Inc-proteins) as well as into the host cytosol with perceived consequences for the pathogenicity of this common venereal pathogen. Recently, small molecules were shown to block the TTS system of Yersinia pseudotuberculosis. Here, we show that one of these compounds, INP0400, inhibits intracellular replication and infectivity of C. trachomatis at micromolar concentrations resulting in small inclusion bodies frequently containing only one or a few reticulate bodies (RBs). 
The intracellular pathogen Chlamydia trachomatis possesses a type III secretion (TTS) system believed to deliver a series of effector proteins into the inclusion membrane (Inc-proteins) as well as into the host cytosol with perceived consequences for the pathogenicity of this common venereal pathogen. Recently, small molecules were shown to block the TTS system of Yersinia pseudotuberculosis. Here, we show that one of these compounds, INP0400, inhibits intracellular replication and infectivity of C. trachomatis at micromolar concentrations resulting in small inclusion bodies frequently containing only one or a few reticulate bodies (RBs). type III secretion system S creening for novel antimicrobials has traditionally been done by scoring for growth inhibition in vitro on artificial media. This approach has over the years led to a limited number of antimicrobial classes. To combat increasing antibacterial resistance, development has focused on modifying compounds within the existing classes rather than identifying small molecules with a completely novel mode of action. Targeting growth and virulence under in vivo-like conditions will likely identify completely new sets of molecules, as recently shown for Vibrio cholerae where a small-molecule inhibitor of the transcriptional activator ToxT, virstatin, prevented both toxin and pili expression, protecting infant mice from colonization (1) . Small molecules belonging to a class of acylated hydrazones of salicyl aldehydes were recently identified (2, 3) that inhibited type III secretion (TTS)-dependent delivery of Yersinia pseudotuberculosis Yop effectors into target cells without inducing a measurable toxicity on the host cells. Neither virstatin nor the Yersinia TTS inhibitors affected bacterial growth in vitro. It is likely that also in vivo, the bacterial multiplication rates are not affected by these novel classes of antivirulence drugs but only their ability to cause pathophysiology and͞or to evade the host innate immune response.
Chlamydia trachomatis is the most common sexually transmitted bacterial disease and the leading cause of preventable blindness worldwide (4) . Chlamydia are Gram-negative, obligate, intracellular bacteria that share a unique biphasic developmental cycle (5) . Infection is initiated by attachment of elementary bodies (EBs) to eukaryotic host cells. A few hours after internalization, infectious but metabolically inactive EBs differentiate into reticulate bodies (RBs), the metabolically active form of Chlamydia. RBs will then replicate within a cytoplasmic vacuole termed inclusion before they redifferentiate to EBs. Upon EB release from the infected host cell, a new round of infection can begin. Throughout their entire time in the host cell, Chlamydia remain within the confinements of the parasitophorous vacuole, which very early during infection exits the endocytic pathway and becomes instead fusiogenic with a subset of exocytic vesicles originating from the ER͞Golgi network and late endosomes (6, 7) .
Like many other Gram-negative pathogenic bacteria, Chlamydia possess a TTS system that enables them to deliver effector proteins into the host cell (8, 9) . C. trachomatis EBs rapidly induces its own entry into host cells, through an internalization process believed to be promoted by the TTS effector protein TARP (10) . During the early phase of infection, C. trachomatis induces and secretes a set of putative type III effectors (Inc-proteins) (11), of which IncG has been shown to specifically interact with the mammalian signal transducer protein 14-3-3␤ at the inclusion membrane (12) . Little is known about the function of these early-phase proteins that are displayed at the interface of intravacuolar Chlamydia and host cell. IncA, a protein induced and secreted during chlamydial mid-cycle, has been demonstrated to be involved in homotypic fusion between Chlamydia-containing vesicles at high multiplicities of infection (13) . In addition to the family of Inc-proteins, other chlamydial proteins secreted into the inclusion membrane have been identified (14, 15) . Moreover, proteins targeted into the host-cell cytosol have been described (16) (17) (18) .
In the absence of a genetic system to modify Chlamydia, the function of most of the Inc proteins still remains unknown, and it has not been possible to elucidate whether Inc-proteins or other type III effector proteins secreted into the inclusion membrane or the host cytosol are required for Chlamydia to undergo a normal infectious cycle.
In this article, we demonstrate that INP0400, a small molecule identified in a TTS inhibitor screen of Y. pseudotuberculosis, without affecting in vitro multiplication, causes a dose-and growth phasedependant inhibition of C. trachomatis RB multiplication. Drug treatment at different stages in the chlamydial developmental cycle reveals a partial block of entry, an inhibition of the translocation of the TTS effectors IncG and IncA during the early and middle phase, respectively, and a bacterial detachment from the inclusion membrane during the late stage concomitant with an inhibition of terminal differentiation from RBs to infectious EBs. (Fig. 1B) was found to inhibit bacterial replication as shown by immunofluorescence microscopy (Fig. 1A) . Inclusion size was affected at concentrations as low as 10 M, without a detectable effect on the number of infected cells. At a concentration of 20 M, inclusions were barely visible ( Fig. 1 A) . However, the number of infected cells was only 5-10% lower as compared with untreated control (data not shown). Electron microscopy, after 30 h of infection in the presence of INP0400, showed a dose-dependant reduction in the size of the inclusion bodies and a concomitant reduction in the number of intracellular bacteria (Fig. 1C ). At 20 M or higher of INP0400, the SIB contained only one or few RBs (Fig. 1C) .
Results
Reinfection in the absence of drug after 48 h treatment with INP0400 revealed a dose-dependant reduction in the number of inclusions (Fig. 2) . A 20-fold reduction was seen with 20 M and an impressive 3-log reduction was observed when using 25 M (Fig.  2) . Cytotoxicity assays performed on the McCoy cells were negative for INP0400 at concentrations Ͻ70 M (data not shown).
Partial Inhibition of EB Entry. C. trachomatis EBs have been shown to be equipped with a TTS apparatus able to secrete one protein, TARP, thought to interact with the actin cytoskeleton, thereby activating the host cell to internalize the organism (10) . To see whether INP0400 had an effect on uptake, McCoy cells were infected by Chlamydia at a MOI of 0.5 by centrifugation of bacteria onto the cells or by a temperature shift. INP0400 at different concentrations was given at the time of infection and removed after 3 h by washing (Fig. 3 ). Both methods of infection resulted in a dose-dependant decrease in the number of cells containing detectable inclusion bodies after 40 h growth in the absence of the drug.
At the highest concentration used (40 M), inhibition of entry was Ϸ40%.
Early Drug Treatment Prevents the IncG-Interacting Host Protein

14-3-3␤ from Decorating Chlamydia-Containing Inclusion Bodies.
The TTS effector protein IncG is synthesized already 2 h postinfection (p.i.) (19) . It localizes to the inclusion membrane and there interacts with the mammalian protein 14-3-3␤ (12) . To see whether INP0400 inhibits IncG translocation, we performed immunofluorescence with antibodies to 14-3-3␤ 24 h after infection with Chlamydia and treatment with INP0400 at 50 M (Fig. 4) . Whereas untreated infected cells accumulated most of their cellular content of 14-3-3␤ to the inclusion membrane, there was no detectable decoration of SIB, leaving 14-3-3␤ evenly distributed in the cytosol as in noninfected cells (Fig. 4) . (16, 20) . However, the function of most of these effector proteins has still to be assigned. Clinical C. trachomatis isolates, mutated in the gene encoding the putative TTS effector protein IncA, have been shown to give rise to multiple inclusions after infection with a high MOI in contrast to the single inclusions typically seen in IncA-producing wild-type isolates (21, 22) . However, intracellular replication of C. trachomatis was not inhibited in the absence of homotypic fusions. IncA transcript can be detected 10-12 h p.i. and continue to be produced during the mid and late phase of the infectious cycle (13) . We therefore infected McCoy cells with C. trachomatis at a MOI of 5 and treated the cells with INP0400 at 50 M after 8 h of infection. As seen in Fig. 5 , this concentration of drug inhibited IncA-mediated homotypic fusion, resulting in a number of distinctly separated SIB, each decorated by 14-3-3␤ as evidence for a successful translocation of IncG, an early-phase TTS effector. In accordance with this finding, we were unable to detect IncA in the inclusion membrane of SIB when following the same treatment protocol (Fig. 6 ). Intermediate concentrations of INP0400 were also tested, showing that concentrations around 50 M INP0400 are required to observe these phenotypes (data not shown). 
INP0400 Treatment During the Late Phase of the Infectious Cycle Results in Bacterial Detachment from the Inclusion Membrane and an
Inhibition of Terminal Differentiation into Infectious EBs. Electronmicroscopic studies have revealed that C. trachomatis RBs are typically found juxtaposed to the inner surface of the inclusion membrane during mid-cycle development (23). It is not known, however, whether this attachment requires effectors delivered by the chlamydial TTS system. Likewise, it is not known whether RB association with the inclusion membrane is required for bacterial multiplication and͞or RB-to-EB conversion. To specifically examine the effect of INP0400 on chlamydial interaction with the inclusion membrane, McCoy cells were infected with C. trachomatis for 24 h (MOI 0.5-1.0) in the absence of drug to obtain inclusions that could be readily visualized by immunofluorescence microscopy (Fig. 7A ). INP0400 at different concentrations was then added to the infected cells. After another 24 h, the infected cells were examined. Untreated cells contained a large inclusion with bacteria filling up the entire inclusion body (Fig. 7B) . In contrast, bacteria in drug-treated cells (25 M and higher) failed to associate with the inclusion membrane (Fig. 7C) , leaving a free rim between the inclusion membrane and the bacteria. If INP0400 was removed after 44 h and infected cells incubated in the absence of the drug for another 4 h, bacteria reassociated with the inclusion membrane (Fig. 7D) .
After incubation for 48 h in the absence of INP0400, conversion of RBs to EBs has occurred, resulting in a high number of infectious units upon reinfection (Fig. 7E) . Addition of the drug after 24 h of infection resulted in a dose-dependant decrease in infectivity after 48 h despite the fact that drug treatment between 24 and 48 h in the infectious cycle had no apparent effect on bacterial growth (Fig.  7C) . Hence, INP0400 inhibits terminal RB-to-EB differentiation during the late cycle. This effect of the drug was reversible (Fig. 7F) . Thus, compared with cells treated from 24 to 48 h in the infectious cycle, infectivity increased by 1-log when INP0400 added at 24 h was removed after 12 h and infected cells were allowed to incubate for another 12 h in the absence of drug (Fig. 7F) .
Discussion
A class of acylated hydrazones was recently identified that inhibited TTS of Y. pseudotuberculosis without affecting the in vitro growth rate (2, 3) . The same class of compounds has also been shown to inhibit TTS of Pseudomonas aeruginosa as well as S. typhimurium (unpublished data), suggesting that these compounds target the secretory apparatus itself rather than individual effector molecules. The obligate intracellular pathogen C. trachomatis also possesses a TTS system believed to deliver a large number of chlamydial proteins into either the inclusion membrane or the host cytosol. So far, only one protein, Tarp, has been shown to be delivered from extracellular EBs upon contact with target cells, whereas the other putative TTS effectors are produced at specific stages during the chlamydial infectious cycle. The differential expression pattern of TTS effectors suggests that they play an instrumental role at different stages in the chlamydial developmental cycle. However, lack of genetic tools has made it difficult to determine whether TTS effectors are needed for Chlamydia to undergo its different developmental phases. There are, however, evidences that TTS effectors promote entry (TARP) and modulate properties of the inclusion membrane to escape from the endosomal pathways, and to promote heterotypic as well as homotypic interactions.
Here, we initiate a chemical genetic approach to dissect a role for Chlamydia TTS during different stages in the infectious cycle of Chlamydia. TTS inhibitors have been screened such that they do not significantly affect the in vitro growth rate of Yersinia. In contrast, in the obligate intracellular pathogens C. trachomatis and C. pneumoniae (L.B., Å.G., C.S., S.M., M.E., P. Nordström, B.H.-N., A. Waldenström, H.W.-W., and S.B., unpublished data), those TTS inhibitors tested exhibited a dose-dependant antibacterial activity, suggesting that the TTS system of Chlamydia is required for the organism to undergo a productive infectious cycle.
The small molecule INP0400 partially inhibited uptake of EBs, suggesting an inhibitory effect on the internalization process. This inhibition, however, was not complete, meaning either that the compound did not completely inhibit translocation of Tarp from EBs or that some internalization may proceed also in the absence of this effector protein. Internalized EBs in the presence of drug converted to RBs, but RB multiplication was inhibited in a dosedependant fashion, resulting in ultimately smaller inclusion bodies (SIB) containing just one or a few RBs.
We demonstrate that early drug treatment prevented the host protein 14-3-3␤ from localizing to the inclusion membrane of SIB, a process known to depend on translocation of the TTS effector IncG into the inclusion membrane. IncG is expressed already 2 h after infection (19) . This correlates well with our finding that infected cells treated 8 h in the infectious cycle result in SIB able to recruit 14-3-3␤ to the membrane, indicative of a normal IncG translocation. Whether early treatment with INP0400 affects translocation of all early TTS effectors is not known. The antibacterial activity of INP0400, however, can not be dependent on an inhibition of TTS translocation in the early phase, because inhibition of RB multiplication was also seen when the drug was added during the chlamydial mid-cycle 3-18 h p.i. During this period, around 10-12 h p.i., IncA is transcribed and localized to the inclusion membrane. This effector protein is firmly linked to the ability of inclusion bodies to undergo homotypic fusions resulting in one single inclusion body in cells that are multiply infected by Chlamydia. Using a high infection dose, we show that homotypic fusions are blocked by INP0400 given at 8 h, a time point in the chlamydial developmental cycle that precedes the onset of IncA production. Although these multiple SIB contained translocated IncG, an early-phase effector, we could not detect IncA in these nonfused inclusion bodies. Based on these data, we argue that INP0400 can inhibit TTS in C. trachomatis. It is tempting to suggest that the inhibitory effect of INP0400 on RB multiplication during the chlamydial mid-cycle is due to an inhibited translocation of other TTS effectors than IncA, because incA mutants of C. trachomatis have been found among clinical isolates (21) .
Little is known about TTS effectors secreted during the late phase of the infectious cycle apart from the chlamydial CADD protein that has been suggested to modulate apoptosis (17) . Whether TTS is needed to trigger differentiation from RBs to EBs is not known. We could demonstrate here that INP0400 treatment during this phase had a dramatic effect on RB-to-EB terminal differentiation, resulting in a dramatic decrease of infectivity upon reinfection. This drug-mediated inhibition of RB-to-EB conversion was associated with a reversible detachment of the RBs from the inclusion membrane. It is not known whether RBs need to associate with the inclusion membrane for their multiplication and differentiation. The findings that host lipids are incorporated into the chlamydial membrane (24, 25) are consistent with capture of host lipids through bacterial binding to the inclusion membrane. For enteropathogenic Escherichia coli, it has been firmly established that this pathogen, through its TTS system, inserts its own receptor into the mammalian cell membrane, to which it then adheres to trigger additional host signaling events (26) . A similar mechanism could explain the attachment seen during normal chlamydial infection. The observed detachment seen in the presence of INP0400 is therefore compatible with an inhibition of chlamydial TTS.
TTS inhibitors represent a new paradigm for treatment of infectious diseases caused by Yersinia spp., Salmonella spp., Shigella spp., and other Gram-negative pathogens that depend on TTS for the dedicated delivery of effector proteins modulating and͞or inhibiting host defenses. A major limitation for clinical use of TTS inhibitors on these extracellular and facultative intracellular pathogens, however, is likely to be due to difficulties in performing in vitro susceptibility testing, requiring the development also of novel diagnostic procedures. If, as our data suggest, TTS is essential for the obligate intracellular pathogen C. trachomatis to undergo a normal infectious cycle, susceptibility testing can be performed as is currently being done by conventional antibiotics. Also, more active TTS inhibitors can be directly screened for by using Chlamydia rather than the extracellular pathogen Yersinia as the target organism. Finally, the exact mode of action for TTS inhibitors can more easily be worked out in Chlamydia, by isolating and characterizing mutants resistant to the drugs. 
